Science Policy For All

Because science policy affects everyone.

Science Policy Around the Web – September 29, 2015

leave a comment »

By: Cheryl Jacobs Smith, Ph.D.

Photo source: capitol via licence

Legislative Policy

Congress moves closer to averting government shutdown with Senate vote

Amidst the controversial language to de-fund Planned Parenthood in a continuing resolution (CR) to keep the federal government solvent, the Senate pushed ahead with a stopgap spending bill to keep federal services running for a few more months – and with no cuts to Planned Parenthood. An earlier link post by Sara Cassidy, M.S., Ph.D. reported that some in Congress were pushing for budget legislation that would de-fund Planned Parenthood written into the CR to fund the National budget. That particular addition to the legislation threatened that the CR would not be passed by the September 30th deadline resulting in a government shutdown. However, since John Boehner, 53rd Speaker of the House, announced his resignation at the end of October, Republican leaders joined by Democrats went forward with a short-term funding measure to keep the government operating without cuts to Planned Parenthood. On Monday, the Senate overwhelmingly advanced the government funding bill by a 77-19 vote. Final passage in the Senate is likely to come Tuesday. The House is expected to vote Wednesday. (Lisa Mascaro, Los Angeles Times)

Pharmaceuticals

FDA OKs Novo Nordisk Diabetes Drug Tresiba

The U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s anti-diabetic drug, Tresiba on Sept. 25. The Denmark-based company behind Tresiba is pleased with the FDA’s approval. “We are very happy with FDA’s decision to approve Tresiba and Ryzodeg as we believe these products offer significant benefits and important treatment options for people with type-1 and type-2 diabetes”, said Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk. Sørensen added that this approval is a milestone for the company. Tresiba was initially disapproved by the FDA due to the lack of data on the risk for heart problems. Tresiba is a long-acting insulin used to control blood sugar levels of type-1 and type-2 diabetics and can last up to 42 hours. Living with type-1 or type-2 diabetes is similar to other chronic disorders where the care and maintenance of the disease encompasses every minute of the day. This longer-acting insulin promises to give some relief. Another positive aspect about the passage of Tresiba is that Novo Nordisk’s North America’s chief medical officer, Todd Hobbs said that “We want to do everything we can to make it as affordable and as broad of an access as we can.” (Julienne Roman, Tech Times)

Environmental News

After a year of stonewalling, Volkswagen finally came clean

Volkswagen stunned two senior officials with the U.S. Environmental Protective Agency (EPA) by admitting the automaker hacked its own cars to deceive U.S. regulators about how much their diesel engines pollute and exceed EPA emission regulations. U.S. officials exposed the deception on September 18, triggering Volkswagen’s admission that it had installed software in its cars to detect when they were being tested and alter settings to conceal the true emissions of 11 million cars sold worldwide. As a result, Volkswagen, the world’s largest automaker by sales, faces EPA fines that could reach $18 billion. (Reuters)

 Have an interesting science policy link?  Share it in the comments!

Advertisements

Written by sciencepolicyforall

September 29, 2015 at 11:00 am

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: